Stock Price & Analysis

Based on the provided data and recent market activity, here's a comprehensive analysis of ATR stock:

Technical Analysis

• Current price at $145.61 with RSI (14) at 35.51 indicates the stock is approaching oversold territory
• Price is trading below both 5-day ($146.51) and 10-day ($144.74) moving averages, suggesting short-term weakness
• MACD shows slight bearish momentum with -3.37 reading, though MACD histogram (0.02) indicates potential bottoming

Recent Performance & News

• Q4 2024 earnings beat expectations with EPS of $1.52 vs $1.26 consensus, showing 20.63% surprise
• Revenue slightly missed at $848.09M vs consensus, though up from $838.48M year-over-year
• Stock has underperformed S&P 500 YTD with only 0.8% gain vs market's 3.1%

Analyst Sentiment

• Recent analyst coverage maintains bullish ratings while adjusting price targets
• Average analyst target price indicates 24.76% upside potential to $183.00

Recommendation SELL based on:

1. Technical indicators showing bearish momentum
2. Trading below key moving averages
3. Post-market weakness (-1.70%)
4. Current price ($145.61) near resistance level of $146.94 (Fibonacci R1)

Consider re-entering once price stabilizes above 5-day MA ($146.51) or RSI moves out of oversold territory.

Based on the provided data and references, I'll analyze ATR's price prediction for 2025:

Technical Analysis:

The stock is currently in a downward trend, trading at $145.61 as of Feb 24, 2025. Key technical indicators show:

• RSI at 38.16 indicates slightly oversold conditions
• MACD shows bearish momentum with -3.37
• Trading below both 60-day SMA ($158.42) and 200-day SMA ($154.38)

Analyst Consensus & Price Targets:

According to Wall Street analysts:

• Consensus Rating: Strong Buy
• Average Price Target: $181.60 (24.69% upside potential)
• Price Target Range: $160.00 - $215.00

Growth Projections:

Revenue and EPS forecasts for 2025:

• Revenue: Expected to grow 2.82% to $3.68B
• EPS: Projected to increase 1.44% to $5.61

Key Drivers for 2025:

1. Industry Outlook:

• Positive momentum in healthcare sector
• Strong demand for medical instruments and supplies

2. Company Fundamentals:

• Solid Q4 2024 earnings beat with EPS of $1.52 vs $1.26 expected
• Consistent revenue growth trajectory

Price Prediction for 2025:

Based on analyst forecasts and technical analysis, ATR stock price is likely to reach:

• Conservative case: $160 (9.88% upside)
• Base case: $183.75 (26.19% upside)
• Optimistic case: $215 (47.65% upside)

The most probable scenario is the base case of $183.75, supported by:

• Strong analyst consensus
• Consistent earnings growth
• Solid market position in medical instruments sector

The S1 support level for ATR Stock is $142.6 ,The R1 resistant level for ATR Stock is $148.5.

As of the end of day on 2025-02-27, the price of ATR Stock was $145.63.

The target price for ATR Stock according to analyst rating is 181.60, with the highest price target at 205.00 and the lowest at 160.00. Analysts have a Strong Buy rating on ATR Stock overall.

The market cap of ATR is $9.7B.

Based on the technical and fundamental data analysis, ATR appears to be slightly overvalued at the current price of $145.61. The stock's RSI reading of 35.51 indicates it has entered oversold territory, suggesting potential buying opportunity despite valuation concerns. The current P/E ratio of 29.07 and EV/EBITDA of 12.98 are both above industry averages, indicating premium pricing. The stock is trading below its 60-day SMA of $158.42 and 200-day SMA of $154.38, showing bearish technical signals. Recent Q4 earnings beat estimates by 20.63%, but the stock's price reaction suggests market participants remain cautious about the valuation.

AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. The Company operates through three segments: Aptar Pharma, Aptar Beauty and Aptar Closures. Aptar Pharma segment supplies nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and healthcare markets worldwide and supplies elastomer for injectable primary packaging components worldwide. The segment also provides services designed to accelerate and de-risk the development and regulatory approvals of drugs using drug delivery devices. The Aptar Beauty segment sells a variety of pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care and home care markets. Aptar Closures segment primarily sells dispensing closures.

Based on the available data and market analysis, AptarGroup (ATR) stock is projected to reach $210-220 by 2030, driven by consistent earnings growth and strong market position in consumer-product dispensing systems. The company's recent Q4 2024 performance showing a 20.63% earnings surprise and successful track record of beating consensus estimates supports this bullish outlook. The company's strategic focus on innovation in surgical treatments and expanding market presence, coupled with its healthy debt-to-equity ratio of 0.17, positions it well for sustained long-term growth.

ATR has a total of 13800 employees.